RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
   Small Cell Carcinoma
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Small Cell Carcinoma Channel

subscribe to Small Cell Carcinoma newsletter
Latest Research : Cancer : Lung : Small Cell Carcinoma

   EMAIL   |   PRINT
Survival Not Improved With Dose-Dense Chemotherapy for Small-Cell Lung Cancer

May 4, 2005 - 5:26:00 PM
Overall survival and 2-year survival were similar in the two arms. The treatment duration was shorter in the dose-dense arm than in the standard arm, but this difference was not statistically significant.

 
[RxPG] A randomized trial has found that a dose-dense regimen of chemotherapy with blood progenitor cell support did not improve survival compared with standard-dose chemotherapy in patients with small-cell lung cancer (SCLC). However, patients who received the dose-dense regimen had fewer infections and fewer days of treatment than patients who received standard chemotherapy.

Long-term survival in patients with SCLC is poor. Studies that have tested different dose intensities of various chemotherapy regimens for SCLC have yielded conflicting results. Paul Lorigan, M.D., of Christie Hospital Manchester in England, and colleagues conducted a phase III randomized trial to determine whether doubling the dose density of ifosfamide, carboplatin, and etoposide (ICE) chemotherapy with blood-progenitor-cell support improved survival compared with standard ICE chemotherapy in patients with SCLC who had a relatively good prognosis. A total of 318 patients were randomly assigned to receive ICE chemotherapy every 4 weeks (standard arm) or every 2 weeks (dose-dense arm).

Overall survival and 2-year survival were similar in the two arms. The treatment duration was shorter in the dose-dense arm than in the standard arm, but this difference was not statistically significant.



Publication: May 4 Issue of Journal of the National Cancer Institute
On the web: jncicancerspectrum.oupjournals.org 

Advertise in this space for $10 per month. Contact us today.


Related Small Cell Carcinoma News
Survival Not Improved With Dose-Dense Chemotherapy for Small-Cell Lung Cancer

Subscribe to Small Cell Carcinoma Newsletter

Enter your email address:


 Additional information about the news article
The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Visit the Journal online at http://jncicancerspectrum.oupjournals.org/.
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)